John Tagliamonte is an experienced leader in the biopharmaceutical and biotechnology sectors, currently serving as SVP of Business Development at Tract Bio, where efforts focus on developing innovative FAP-activated cancer drugs. Tagliamonte also holds the position of Corporate Development Lead at Adecto Pharmaceuticals, working on novel therapies for triple-negative breast and gastrointestinal cancers. Additionally, Tagliamonte contributes as an advisory board member at PhagePro, promoting cholera prevention using natural bacteriophages. Previous roles include Senior Business Advisor at Harbour BioMed and Axonis Therapeutics, and CEO of Mellitus, LLC, where advancements in diabetes testing were prioritized. Tagliamonte co-founded Tantu Therapeutics, Inc. to create biotherapeutics for inflammatory bowel disease, and has been involved with various startups and initiatives related to gene therapy and cancer treatment. Educational credentials include a B.S. in Molecular Biology from Tufts University and an MBA in Global Marketing from Boston College.
This person is not in the org chart
This person is not in any teams
This person is not in any offices